Related references
Note: Only part of the references are listed.Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS
Megan Fracol et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2011)
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
Kousaku Mimura et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial
Ritesh Patil et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2010)
Overcoming Cancer Immune Tolerance and Escape
Guy T. Clifton et al.
CLINICAL CANCER RESEARCH (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Longterm Followup Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients
Jeremy D. Gates et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence - From US Military Cancer Institute clinical trials group study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2008)
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
Kimberly A. Chianese-Bullock et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
Brian J. Czerniecki et al.
CANCER RESEARCH (2007)
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
GE Peoples et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients
MT Hueman et al.
CLINICAL CANCER RESEARCH (2005)
Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours
PA Sotiropoulou et al.
BRITISH JOURNAL OF CANCER (2003)
Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant
DG McNeel et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2003)
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast
HM Kuerer et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2002)
Share Paper
